FORA Capital LLC Takes Position in HealthEquity, Inc. (NASDAQ:HQY)

FORA Capital LLC bought a new position in HealthEquity, Inc. (NASDAQ:HQY) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,582 shares of the company’s stock, valued at approximately $536,000.

Other hedge funds have also modified their holdings of the company. Fred Alger Management LLC purchased a new stake in shares of HealthEquity during the 4th quarter valued at about $1,583,000. Frontier Capital Management Co. LLC bought a new stake in HealthEquity during the 4th quarter valued at about $4,199,000. Deutsche Bank AG boosted its holdings in shares of HealthEquity by 25.9% in the fourth quarter. Deutsche Bank AG now owns 118,199 shares of the company’s stock valued at $11,341,000 after purchasing an additional 24,289 shares during the period. EP Wealth Advisors LLC lifted its holdings in shares of HealthEquity by 9.7% in the 4th quarter. EP Wealth Advisors LLC now owns 4,555 shares of the company’s stock worth $437,000 after buying an additional 403 shares during the period. Finally, Cetera Investment Advisers grew its holdings in HealthEquity by 6.7% during the 4th quarter. Cetera Investment Advisers now owns 3,572 shares of the company’s stock worth $343,000 after acquiring an additional 225 shares in the last quarter. 99.55% of the stock is owned by hedge funds and other institutional investors.

HealthEquity Price Performance

NASDAQ:HQY opened at $90.44 on Friday. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.51. HealthEquity, Inc. has a 12 month low of $65.01 and a 12 month high of $115.59. The firm has a market cap of $7.82 billion, a P/E ratio of 82.97, a price-to-earnings-growth ratio of 1.60 and a beta of 0.45. The stock has a 50 day moving average of $88.05 and a two-hundred day moving average of $96.63.

Insider Buying and Selling at HealthEquity

In related news, Director Robert W. Selander sold 5,750 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $111.29, for a total value of $639,917.50. Following the completion of the sale, the director now owns 78,219 shares of the company’s stock, valued at approximately $8,704,992.51. This represents a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Michael Henry Fiore sold 8,881 shares of the firm’s stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $78.26, for a total transaction of $695,027.06. Following the sale, the executive vice president now owns 56,655 shares of the company’s stock, valued at $4,433,820.30. This represents a 13.55 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,381 shares of company stock worth $1,781,432. Corporate insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HQY. Wells Fargo & Company lifted their price target on HealthEquity from $110.00 to $125.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Raymond James upgraded shares of HealthEquity from an “outperform” rating to a “strong-buy” rating and cut their price target for the company from $120.00 to $115.00 in a research note on Tuesday, March 25th. KeyCorp reduced their price objective on HealthEquity from $110.00 to $100.00 and set an “overweight” rating for the company in a research note on Wednesday, April 16th. Barrington Research restated an “outperform” rating and set a $112.00 target price on shares of HealthEquity in a research report on Friday, April 11th. Finally, The Goldman Sachs Group lowered their price objective on HealthEquity from $107.00 to $94.00 and set a “neutral” rating on the stock in a research report on Thursday, March 27th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, HealthEquity currently has a consensus rating of “Buy” and a consensus target price of $111.75.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.